Clinical Considerations: SACP: The Skinny on GLP1 Agonists (Part 2)

Recent trends indicate the GLP-1 market will exceed $100 billion by 2030; this is not a surprise for the health care system as discussion and use of these medications within this class has continued to soar.  As the prescribing of these medications continue to increase, pharmacists in all settings must be well versed to ensure they are able to provide appropriate counseling, education, and adjustments for patients and provide clinical insight to the healthcare team.    The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.